Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Skip to main content

Practical Considerations of Setting up a Research Consortium

By October 4, 2010December 5th, 2023Awareness

Ed. note: This is the third post by Dr. Kim Hunter-Schaedle recapping the Conference on Clinical Research for Rare Diseases to see the first post please click here.

There are many positive aspects to setting up a research consortium. Not least, funding agencies like them, because they usually mean ‘bang for the buck’ – the researchers have already self organized and come up with a collaborative plan.  However setting up a rare disease clinical research consortium presents challenges, especially for running clinical trials. Rare disease clinical trials must be kept small because there will always be a limited access to patients. Despite this one cannot underestimate the cost of a rare disease trial – many of the set up costs for a trial are fixed and must be spent whether the trial includes 100 patients or 1,000.

There are some practical issues that need to be considered up front. The consortium head must recognize this commitment as a top priority. All sites that participate in the consortium must have a committed team – not just a sole investigator at a site. Participating researchers must recognize that it might take a long time before seeing productivity or success. In terms of publishing results when they do come, senior established investigators should consider the opportunity to give more visibility to junior investigators who are still establishing their careers.

Funding is also a key issue. Although funding is committed for the consortium, the researchers should be on the lookout for additional funding that can be brought in to expand the programs of the consortium. This may be federal, foundation or institutional funding.

Close Menu